Eli Lilly Stock Eyes $1,100 After Strong Q1 Results and GLP-1 Growth
Eli Lilly Stock Eyes $1,100 After Strong Q1 Results and GLP-1 Growth
Eli Lilly is back in the spotlight after a powerful first-quarter performance renewed investor confidence in the pharmaceutical giant’s growth story.
The company reported first-quarter 2026 revenue of $19.8 billion, up 56% from a year earlier, driven mainly by strong demand for Mounjaro and Zepbound. Non-GAAP earnings per share rose to $8.55, while management lifted full-year revenue guidance to $82 billion to $85 billion.
Why Investors Are Watching Eli Lilly Closely
The big question now is whether Eli Lilly shares can move above the $1,100 level. According to 24/7 Wall St., its price target for Eli Lilly is $1,164.85, implying upside from the cited price of $1,015.75. The publication rated the stock a buy, supported by earnings growth, analyst confidence, and strength in the company’s obesity and diabetes medicines.
The strongest driver behind the bullish outlook is Lilly’s GLP-1 franchise. Mounjaro generated $8.66 billion in first-quarter revenue, up 125% year over year. Zepbound added $4.16 billion, rising 80%.
Mounjaro and Zepbound Remain Key Growth Engines
Mounjaro, used for diabetes treatment, and Zepbound, used for weight management, have become central to Eli Lilly’s revenue expansion. Demand remains strong in the United States and international markets, although lower realized prices partly reduced the benefit of volume growth.
Outside the United States, Lilly reported revenue growth of 81%, supported by rising Mounjaro volume. However, pricing pressure appeared in some markets, including China, where reimbursement changes affected realized prices.
Foundayo Adds a New Growth Opportunity
Another major focus is Foundayo, Lilly’s oral GLP-1 pill, also known as orforglipron. Lilly said the FDA approved Foundayo for adults with obesity or overweight with weight-related medical problems. The company highlighted that the pill can be taken without food or water restrictions, which may make it easier for more patients to use.
This matters because many GLP-1 treatments are injections. A convenient oral option could expand Lilly’s addressable market and strengthen its position against competitors.
Pipeline Progress Supports the Bull Case
Lilly also reported progress across its drug pipeline. Retatrutide, a triple agonist being studied for type 2 diabetes, achieved positive Phase 3 results. The company also reported advances in oncology, immunology, and obesity-related studies.
For investors, this pipeline matters because Lilly’s valuation depends not only on today’s sales but also on whether future medicines can continue the company’s growth trend.
Risks Still Remain
Despite the positive momentum, risks are clear. Lilly reported that lower realized prices reduced revenue growth, especially in Mounjaro and Zepbound. The company also recorded $584 million in acquired IPR&D charges and $279 million in asset impairment, restructuring, and other special charges during the quarter.
Competition is another concern. The obesity and diabetes treatment market is large, but rivals are investing heavily. If pricing pressure increases or new competitors gain share, Lilly’s stock could face pressure.
Can Eli Lilly Reach $1,100?
Based on current momentum, the path to $1,100 appears possible, especially if Mounjaro and Zepbound continue growing and Foundayo launches successfully. 24/7 Wall St. projected a 12-month target above that level, but the forecast depends on strong execution, continued demand, and controlled pricing pressure.
In simple terms, Eli Lilly’s story remains strong, but not risk-free. The company is benefiting from one of the most important healthcare trends in years: treatments for obesity, diabetes, and metabolic disease. If that trend continues, the stock could have more room to rise.
Bottom Line
Eli Lilly’s first-quarter results gave investors fresh reasons to be optimistic. Revenue growth was strong, earnings beat expectations, guidance moved higher, and the company’s GLP-1 pipeline gained more attention. The stock’s move toward $1,100 will likely depend on whether Lilly can keep turning medical innovation into durable revenue growth.
This article is for news and educational purposes only and is not financial advice.
#EliLilly #LLYStock #GLP1 #PharmaStocks #SlimScan #GrowthStocks #CANSLIM